TrialsgrambetaRCTs are beautiful

ASCEND-D

2021

Anaemia Studies in CKD: Daprodustat — Dialysis

In 2,964 dialysis patients with anaemia, the oral HIF prolyl-hydroxylase inhibitor daprodustat was non-inferior for haemoglobin and cardiovascular safety compared with erythropoiesis-stimulating agents.

Result

Efficacy: Change in haemoglobin; major adverse cardiovascular eventsHR 0.93 (95% CI 0.81-1.07)

Below 1 favours daprodustat, above 1 favours erythropoiesis-stimulating agents.

Also reported: Haemoglobin non-inferior;

Original publication
Subtopic
HIF-PHI anaemia
Design
Open-label RCT
Relevance
Important: one of several pillars.
Source
Singh AK, et al. N Engl J Med. 2021;385(25):2325-2335.doi 10.1056/NEJMoa2113379

Discussion & critique

Supported approval of an oral anaemia agent for dialysis patients; non-dialysis use is more cautious.

Discussed in podcasts